Objective Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy,
particularly in Helicobacter pylori (HP)-infected subjects. We determined the association …

(PPI) use is associated with a 2.4-fold increase in the risk of gastric cancer in patients who
received Helicobacter pylori eradication therapy. 1 This is an important finding given that the …

Gastric cancer remains one of the leading cancers in the world with a high mortality,
particularly in East Asia. Helicobacter pylori infection accounts for the majority of the …

Objective The association between proton pump inhibitor (PPI) use and gastric cancer
related to Helicobacter pylori eradication has not been fully investigated in geographical …

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an
increased risk of gastric cancer compared with new users of histamine-2 receptor …

Helicobacter pylori (H. pylori) infection is the most important risk factor for gastric cancer
(GC) development through the Correa's gastric carcinogenesis cascade. However, H. pylori …

Proton pump inhibitor (PPI) use leads to hypergastrinaemia, which has been associated with
gastrointestinal neoplasia. We evaluated the association between PPI use and risk of gastric …

Objective Proton pump inhibitors (PPIs) are among the most commonly prescribed drugs.
Concerns have been raised about a potentially increased risk of gastric cancer following …

Summary Background Proton‐pump inhibitors (PPIs) are suspected to increase the risk of
gastric cancer. Aim To assess the risk of gastric cancer associated with the use of PPIs …

Introduction: The use of proton-pump inhibitors (PPI) may be associated with an increased
risk of gastric cancer (GC). Objective: To review and meta-analyse available literature …